Anti-inflammatory effect of statin is continuously working throughout use: a prospective three time point 18F-FDG PET/CT imaging study

Int J Cardiovasc Imaging. 2019 Sep;35(9):1745-1753. doi: 10.1007/s10554-019-01584-y. Epub 2019 Jul 16.

Abstract

No data exist whether statins have robust anti-inflammatory effects of atherosclerotic plaques primarily during the early treatment period or continuously throughout use. This prospective three time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) study of the carotid artery assessed anti-inflammatory effects of statin during the early treatment period (initiation to 3 months) and late treatment period (3 months to 1 year) and their correlation with lipid and inflammatory profile changes during a year of therapy. Nine statin-naïve stable angina patients with inflammatory carotid plaques received 20 mg/day atorvastatin after undergoing initial 18F-FDG PET/CT scanning of carotid arteries and ascending thoracic aorta, and then completed serial 18F-FDG PET/CT imaging at 3 and 12 months whose data were analyzed. The primary outcome was the inter-scan percent change in target-to-background ratio (ΔTBR) within the index vessel. At 3 months of atorvastatin treatment, mean serum low-density lipoprotein cholesterol (LDL-C) level decreased by 36.4% to < 70 mg/dL (p = 0.001) and mean serum high-density lipoprotein cholesterol level increased to > 40 mg/dL (p = 0.041), with both maintained with no further reduction up to 1 year (p = 0.516 and 0.715, respectively) while mean serum high sensitivity C-reactive protein level only numerically decreased (p = 0.093). The index vessel ΔTBR showed continuous plaque inflammation reduction over 1 year, by 4.4% (p = 0.015) from the initiation to 3rd months and 6.2% (p = 0.009) from 3rd months to 1 year, respectively, without correlation with lipid profile changes. The ΔTBR of the bilateral carotid arteries and ascending aorta also continuously decreased from 3 months to 1 year. Three time point 18F-FDG PET/CT imaging demonstrates that statin's anti-inflammatory effect continues throughout its use up to 1 year, even though yielding stable below-target plasma LDL-C levels at 3 months.

Keywords: 18F-FDG PET/CT; Low-density lipoprotein cholesterol; Statin.

MeSH terms

  • Aged
  • Anti-Inflammatory Agents / therapeutic use*
  • Aorta, Thoracic / diagnostic imaging
  • Aorta, Thoracic / drug effects*
  • Aorta, Thoracic / pathology
  • Aortic Diseases / diagnostic imaging
  • Aortic Diseases / drug therapy*
  • Aortic Diseases / pathology
  • Atherosclerosis / diagnostic imaging
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / pathology
  • Biomarkers / blood
  • C-Reactive Protein / metabolism
  • Carotid Arteries / diagnostic imaging
  • Carotid Arteries / drug effects*
  • Carotid Arteries / pathology
  • Carotid Artery Diseases / diagnostic imaging
  • Carotid Artery Diseases / drug therapy*
  • Carotid Artery Diseases / pathology
  • Cholesterol, LDL / blood
  • Female
  • Fluorodeoxyglucose F18 / administration & dosage*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Middle Aged
  • Plaque, Atherosclerotic
  • Positron Emission Tomography Computed Tomography*
  • Predictive Value of Tests
  • Prospective Studies
  • Radiopharmaceuticals / administration & dosage*
  • Time Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Biomarkers
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • C-Reactive Protein